1. Introduction {#s0005}
===============

Vagus nerve stimulation (VNS) therapy has been widely used. The most common stimulation-associated side effects are voice alteration, hoarseness, throat and neck pain, headache, cough, and dyspnea [@bb0005]. The most severe side effects of VNS therapy are bradycardia and cardiac asystole [@bb0010]. We encountered a patient with symptomatic bradycardia due to VNS who underwent cardiac pacemaker (PM) implantation and resolved symptomatic bradycardia. We hypothesized that risk factors for such bradycardia may exist, identification of which would help prevent VNS-induced critical arrhythmia.

2. Methods {#s0010}
==========

A search for medical papers on PubMed and Google Scholar using the key words "vagus nerve stimulation", "arrhythmia", and "bradycardia" revealed 14 papers with 21 patients, not including our case.

We compared patients with VNS-induced arrhythmia (arrhythmia group, n = 22) and patients without such arrhythmia (control group, n = 29). The control group comprised all other patients who underwent VNS implantation in our facility between 2011 and 2014 and had not developed any VNS-induced arrhythmia for more than four years. Inclusion criteria for the control group were: 1) \> 4 years follow-up; and 2) surgery performed by the same surgeon (AF).

We statistically compared each factor between groups, using the Mann--Whitney rank-sum test and Fisher\'s exact test as appropriate. Statistical significance was set at p \< 0.05. All analyses were performed using Sigma Plot 14 software (Systat Software, San Jose, CA).

3. Case report {#s0015}
==============

A 43-year-old, right-handed man was admitted to our hospital due to loss of consciousness (LOC). At 17-years-old, he experienced a right temporal lobe contusion in a motor cycle accident. The patient started to exhibit focal impaired awareness seizures and focal to bilateral tonic-clonic seizures at 27 years old, followed by psychiatric symptoms and accompanying delusions and hallucinations from his early thirties. Temporal lobe epilepsy and epileptic psychosis were diagnosed in his early thirties and he was followed by a local psychiatrist. As his epilepsy had been drug-resistant, he was referred to our hospital. He was on topiramate 200 mg/day, carbamazepine (CBZ) 400 mg/day and risperidone 4 mg/day when he visited our hospital. He underwent long-term video-electroencephalography (VEEG), brain magnetic resonance imaging (MRI), ^123^I-iomazenil single-photon emission computed tomography (IMZ-SPECT), 2-\[^18^F\]fluoro-2-deoxy-[d]{.smallcaps}-glucose positron emission tomography (FDG-PET), and neuropsychiatric tests. Interictal VEEG showed frequent epileptiform discharges in the right frontotemporal area, while ictal VEEG right frontotemporal rhythmic activities with short periods of loss of awareness and mouthing movements followed by postictal confusion. MRI, FDG-PET and IMZ-SPECT were all concordant, showing a right mesial temporal seizure onset zone. We diagnosed right temporal lobe epilepsy. At 36 years old, he underwent right frontotemporal invasive monitoring. The invasive monitoring showed a seizure onset area arising from the mesial temporal lobe, quickly spreading to the right frontal area. We therefore performed right temporal lobectomy. Weekly seizures reduced to monthly. VNS treatment was then started at 37-years-old for residual seizures. Intraoperative VNS stimulation did not induce any electrocardiographic (ECG) changes. Generalized seizures disappeared, but from 40 years old he sometimes exhibited sudden LOC, differing in character from the habitual seizures. At first, we regarded these sudden LOC as epileptic seizures and continued to adjust the regimen of anti-seizure drugs (ASDs). As he exhibited sudden LOC and fell weekly at this point, he was placed under VEEG monitoring, which revealed bradycardia for several seconds during sleep. As VNS reproducibly caused arrhythmia including bradycardia, atrioventricular (AV) block, and a short period of cardiac arrest ([Fig. 1](#f0005){ref-type="fig"}), symptomatic bradyarrhythmia with third-degree AV block induced by VNS was diagnosed and a PM was implanted. When implanting the PM, we conducted an electrophysiological study while changing the output for VNS and decided to position the pacemaker where it would not over-sense stimulation from VNS.Fig. 1A) Critical atrioventricular (AV) block did not occur when vagus nerve stimulation (VNS) was turned off, according to pressure in bilateral carotid arteries. B) With the 1.75-mA output current of VNS, cardiac arrest (arrow) lasted 15 s. C) Complete AV block (arrow) was also detected.Fig. 1

At this time, the patient was on levetiracetam (LEV) 3000 mg/day, CBZ 400 mg/day and risperidone 4 mg/day. Since implantation of the PM, the patient has remained free of sudden LOC.

3.1. Ethics approval {#s0020}
--------------------

Written informed consent for publication of case details was obtained from our patient. This study was approved by the ethics committee at Seirei Hamamatsu General Hospital.

4. Results {#s0025}
==========

All clinical data are shown in [Table 1](#t0005){ref-type="table"}. The 22 patients [@bb0005], [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070] in the arrhythmia group comprised of 8 females and 16 males (mean age, 39 years; range, 8--59 years), while the 29 patients in the control group comprised of 11 females and 18 males (mean age, 31 years; range, 9--52 years). The arrhythmia group was significantly older than the control group (p = 0.038). Epilepsy onset occurred at an older age in the arrhythmia group (mean age, 35.8 years; range, 2--59 years) than in the control group (mean age, 8.6 years; range 0.3--43 years; p \< 0.001). The output current of VNS was significantly lower in the arrhythmia group (median, 1.0 mA) than in the control group (median, 2.0 mA; p \< 0.001). The duty cycle of VNS was lower in the arrhythmia group (median, 10%) than in the control group (median, 15%; P = 0.028). No significant difference in the number of times an ASD was used (p = 0.097) was apparent between groups. However, concomitant psychiatric disorder (p = 0.034) and usage of psychotropic drugs (p \< 0.001) were both significantly more frequent in the arrhythmia group than in the control group. New onset syncopal events differing in character from the habitual seizures were seen only in the arrhythmia group (p \< 0.001).Table 1Reviewed patients and our case. Onset, epileptic seizure onset; VNS, vagus nerve stimulation; CPS, complex partial seizure; GTC, generalized tonic--clonic seizure; sGTC, secondary GTC; LOC, loss of consciousness; n.a, not available; ASD, anti-epilepsy drug; LEV, levetiracetam; PER, perampanel; CBZ, carbamazepine; OXC, oxcarbazepine; LTG, lamotrigine; CLB, clobazam; CLZ, clonazepam; PB, phenobarbital; PRM, primidone; VPA, valproate; TPM, topiramate; PHT, phenytoin; FMB, felbamate; BZP, benzodiazepine; GBP, gabapentin; ZNS, zonisamide; DM, diabetes mellitus; AV block, atrioventricular block.Table 1AuthorAge \[years\]SexOnset \[years\]Age at VNS \[years\]Main seizureVNS induced symptomsVNS outputDuty cycleAEDOther medicationConcomitant symptomsVNSTatum 199938Fn.a38CPSn.a1 mAn.aPHT/lorazepam/tiagabinen.aAnxietyDeactivation57Mn.a57Partial seizuren.a1 mAn.aLTG/PRMOlanzapine/sertralineEncephalopathy/depression/alcohol abuse/Deactivation38Mn.a38Partial seizuren.a1 mAn.aCBZ/VPA/vigabatrinn.aLeft encephalomalaciaDeactivation42Mn.a42Partial seizuren.a\> 1 mAn.aTPM/FMB/PHT/PBTrifluoperazineEncephalopathy/multiple handicaps/autismDose decreasedAsconape 199956Mn.a56CPSn.a1 mAn.aLTG/PRMOlanzapine/sertralineEncephalopathy/pulmonary disease/hypertensionDeactivationAli 200453M453GTC/atypical absencen.a1 mAn.aCBZ/VPAn.aEncephalopathyDeactivation40Mn.a40GTC/CPS/myoclonusn.a1 mAn.aCBZ/VPAn.aEncephalopathyDeactivation42Fn.a42CPSn.a1.25 mAn.aGBP/CZPDM/vasodilatorDiabetes/hypertension/1st degree AV blockDose decreasedSrinivasan 200440Fn.a40Partial seizureNausea/vomiting/lightheadedness/palpitationn.an.an.an.an.aContinuedAdresh 200732F1432CPSn.a1 mAn.aOXC/FMBn.an.aContinued52Mn.a52Partial seizuren.a1 mAn.aPHT/TPMn.aDepression/1st-degree AV blockContinued59F259GTCn.a1 mAn.aCBZ/VPA/CLBn.aBitemporal sclerosisContinuedKoeing 20088F3 m8Multiple typesImprovedn.an.aVPA/FMB/BZPn.aRespiratory sinus arrhythmiaContinuedAmark 200817M5 m15CPSSudden LOC uncontrollable fall1.75 mA10%VPA/GBP/acetazolamiden.an.aDeactivationBorusiak 200913M57CPS without sGTCSignificant increase in seizure frequency2.25 mA10%PB/FMB/ZNSCalcium/vitamin Dn.aDeactivationIrarte 200947F1238CPS/status epilepticusNew events of dizziness, unsteadiness1.75 mA10%PGB/CZP/LEVn.aPsychogenic non-epileptic spellDeactivationClark 201213M22GTCSyncope/obtundation1.25 mA8%CZP/ZNS/RFMn.aSepto-optic dysplasiaRevision/continuedShanker 201355Mn.a47Partial seizure/sGTC/drop attackSudden increase in frequency of atonic spells2.25 mA16%LEV/PGBn.aEncephalopathy/cerebral anoxic brainDeactivationSchevchuck 201440Mn.a39CPS without sGTCNew type of seizuren.a10%LCM/LTG/LEV/PGBEncephalopathyContinuedCantarin 201613F23Drop attack/myoclonusNew attack with sudden fall/LOC1.25 mA10%VPAn.an.aDose decreasedPascual 201556M942CPSSyncope/lightheadedness/LOC2.75 mA12%LEV/TPMAlprazolamAnxietyDeactivationOur case47M2737CPSSudden LOC with uncontrollable fall1.75 mA10%LEV/CBZRisperidoneEpileptic psychiatric disorderContinued with pacemaker[^1]

5. Discussion {#s0030}
=============

From our data and another study assessing the relationship between VNS and sudden unexpected death in epilepsy [@bb0075], the VNS dose and duty cycle themselves did not appear directly linked to arrhythmia. This stimulation might not directly affect cardiac conduction, but indirect stimulation of the central nervous system involving the cardiac conduction system might cause bradycardia. If the bradycardia had been induced by direct stimulation, the control group (which showed both higher output current and higher duty cycle) would have been expected to show a higher prevalence of arrhythmia. Ali et al. [@bb0025] speculated that activation of the afferent pathway for the left vagal nerve has wide-ranging effects on multiple systems and pathways, and may result in activation of multiple other synaptic pathways with influences on cardiac rhythm. This might be the mechanism underlying arrhythmia.

In this study, the arrhythmia group was significantly older than the control group. Arrhythmia associated with vasovagal syncope is reportedly seen most often in the adult population [@bb0080], [@bb0085]. Increased hypersensitivity of the vagus nerve induced symptomatic arrhythmia even without relatively stronger stimulation in our case. We therefore suggest patients with VNS be monitored the long term. In the case of repetitive syncopal events seen, not only an ECG but also prolonged ECG using a Holter ECG or loop recorder are recommended [@bb0090].

Future work is needed to validate these findings from a multi-center reports with a greater number of patients.

6. Conclusion {#s0035}
=============

Even though arrhythmia could become symptomatic, most cases were treated as new-onset epileptic seizures with adjustment of ASDs. To interrupt prolonged cardiac asystole in VNS treatment patients, clinicians should be alert to the possibility of new-onset syncopal events when they differ from habitual seizures.
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[^1]: F, female; M, male; m, months; Onset, epileptic seizure onset; VNS, vagus nerve stimulation; CPS, complex partial seizure focal impaired awareness seizure; GTC, generalized tonic--clonic seizure; sGTC, secondary GTC (focal to bilateral tonic-clonic seizure); LOC, loss of consciousness; n.a, not available; AED, anti-epilepsy drug; LEV, levetiracetam; PER, perampanel; CBZ, carbamazepine; OXC, oxcarbazepine; LTG, lamotrigine; CLB, clobazam; CLZ, clonazepam; PB, phenobarbital; PRM, primidone; VPA, valproate; TPM, topiramate; PHT, phenytoin; FMB, felbamate; BZP, benzodiazepine; GBP, gabapentin; ZNS, zonisamide; DM, diabetes mellitus; A-V block, atrioventricular block.
